Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Might Change Timing of Drug Price Revisions from April amid Medical DX Push
October 24, 2022
- Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
- Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
- Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
- PMDA Reviewing New Safety Risks for Evrenzo and More Drugs
October 24, 2022
- With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
- LDP Project Team to Present Proposal for FY2023 Drug Price Revision and Budget Planning
October 21, 2022
- COVID Booster Interval to Be Shortened to “At Least 3 Months”
October 20, 2022
- Silgard 9’s Label Updated to Add Long-Term Follow-Up Study Data
October 19, 2022
- Avigan Secured for COVID-19 to Be Stockpiled for Pandemic Flu: Health Minister
October 19, 2022
- Label Expansions for TS-1, Enhertu on PAFSC Agenda on Oct. 31
October 18, 2022
- Japan Panel Recognizes One More Death Possibly Linked to COVID Jab
October 18, 2022
- Health Ministry Research Team to Vet Recall Rules to Address Supply Disruptions
October 17, 2022
- Include COVID Drug R&D Support in New Economic Package: LDP Health Panel
October 17, 2022
- Pfizer’s Precedex Up for PAFSC Review for Pediatric Indication as Japan’s 1st “Specific Use Drug” on Oct. 28
October 17, 2022
- Japan to Prepare Schedule for DX in Medical Fee Revisions by Next Spring
October 14, 2022
- Lawmakers Call for Starting 9-Valent HPV Vaccination Program in April 2023
October 14, 2022
- Contraindication Lifted for Parmodia in Renal Impairment Patients
October 14, 2022
- Japan Looks to Secure 950,000 Courses of Lagevrio by Year-End amid Twindemic Threat
October 14, 2022
- Govt Eyes Designation of Cefazolin, Other Antibiotics as Key Resources
October 14, 2022
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…